GlassScriptPhysician profile
Innocent Chidera Anunobi
NPI 1588430979
$2,774.75
in general payments reported to CMS, 2019-2025
17 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,240 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,774.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $498.10 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $394.44 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $260.21 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $249.47 | 2024-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $241.62 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $232.04 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $211.12 | 2024-2025 | Qelbree |
| Lundbeck LLC | $175.32 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $161.96 | 2024-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $108.61 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $64.15 | 2025 | Fanapt |
| Tris Pharma INC | $50.84 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $34.90 | 2024 | Quviviq |
| Itamar Medical INC | $31.15 | 2025 | Watchpatone |
| Medicomp INC | $23.42 | 2025 | Telepatch Cardiac Monitor |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $22.57 | 2024 | Relexxii |
| Exact Sciences Corporation | $14.83 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Innocent Anunobi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.